Lindsey McCormack
Freelance Writer
From this contributor
Angelman mice show impaired inhibition of brain signals
Mice lacking a functional copy of UBE3A, the gene missing or mutated in people with the rare developmental disorder Angelman syndrome, show less inhibitory activity than controls do, according to research published 7 June in Neuron.
Angelman mice show impaired inhibition of brain signals
Scanning during sleep effective across autism spectrum
Scanning children’s brains while they sleep is a viable alternative to sedation for infants and toddlers across the entire autism spectrum, according to a study published in the January issue of the Archives of General Psychiatry.
Scanning during sleep effective across autism spectrum
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.